Acumen Pharmaceuticals’ $160 Million IPO

Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal.Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now